BCR and acute myeloid leukemia: Given the extremely rare incidence of the e1a3 Ph chromosome, it is unclear if TKI therapy is effective for this cohort of patients; nonetheless, limited data available suggests that TKIs may be effective alone or in combination with chemotherapy for AML with BCR-ABL1 (Supplementary Table).